Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Ends Research Pact with Arena | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck Ends Research Pact with Arena

Merck, through an affiliate, has decided to discontinue development of MK-1903 and ended its research collaboration with Arena.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck, through an affiliate, has decided to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis, being developed in collaboration with Arena Pharmaceuticals, Inc. Merck has also ended the research collaboration with Arena.

The decision follows the evaluation of results from a recently completed Phase IIa trial. The trial evaluated the safety, tolerability and potential efficacy in patients with dyslipidemia. According to Merck, elevation of HDL cholesterol relative to placebo did not meet the trial’s pre-specified primary objective for efficacy.

“We are disappointed that the trial results did not lead to further development of this program, but it has been a pleasure to work with Merck and we welcome the opportunity to collaborate again,” said Jack Lief, Arena’s president and chief executive officer. “We continue to focus on our other internal and partnered programs and the FDA approval of our lead drug candidate, lorcaserin for weight management.”

“This collaboration has led to excellent scientific interaction,” said Dr. Andrew Plump, vice president Cardiovascular Franchise Worldwide Discovery Head, Merck Research Laboratories. “We look forward to the possibility of partnering with Arena in the future.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters